Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of BEBT-209 in Combination With Carboplatin and Gemcitabine for the Treatment of Advanced Triple-Negative Breast Cancer

NCT06685796 is registered in ClinicalTrials.gov with BeBetter Med Inc as lead sponsor.

NCT NCT06685796
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06685796 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of BEBT-209 in Combination With Carboplatin and Gemcitabine for the Treatment of Advanced Triple-Negative Breast Cancer
Lead sponsor
BeBetter Med Inc
Phase
Phase 2
Overall status
Completed
Start date
April 12, 2023
Completion date
May 29, 2026
Enrollment
65 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced triple-negative breast cancer